ESPEN-EASO标准下住院老年肌少性肥胖患病率及功能状态影响:回顾性与前瞻性观察研究
Prevalence and impact of sarcopenic obesity at hospital admission according to ESPEN-EASO approach on functional status of older adults: results of a retrospective and prospective observational study
研究显示,住院老年患者中肌少性肥胖患病率约11%,与出院后长期死亡率独立相关。住院期间久坐、炎症和营养不良可加剧肌少症,导致肌力、活动能力下降。采用标准化ESPEN-EASO方法有助于识别高危患者。
Introduction
Sarcopenic obesity (SO), a condition characterized by excess adiposity and by concomitant reduction of skeletal muscle mass and strength, is an important cause of adverse health outcomes among older adults [1]. In this population, SO is associated with an increased risk of geriatric syndromes, including falls [2], poor physical function and performance [3,4,5], cognitive impairment [6], metabolic disorders [7], poor quality of life [8], and reduced survival [9]. In the acute geriatric setting, SO is particularly relevant because it is associated with frailty, worse clinical outcomes, and higher mortality rates [10, 11]. Given the global aging of the population and the obesity epidemic, the prevalence of sarcopenic obesity is expected to increase [1]; however, the existence of several definitions and diagnostic approaches [12] has so far hampered its recognition. To this regard, two recent meta-analyses demonstrated a global prevalence of SO in the range of 9–11% [13, 14], increasing to 16% in hospitalized patients and to 23% in those aged 75 years or older [13]; remarkably, only two of the included studies were performed in the hospital setting. Indeed, very few data are available on the prevalence and consequences of SO during hospitalization in older adults. In this respect, a recent investigation using percentage fat mass to define obesity and standardized criteria to diagnose sarcopenia [15] demonstrated that the prevalence of sarcopenia and SO among hospitalized older patients was 21% and 11%, respectively, and that both conditions were independently associated with increased long-term mortality after discharge [11]. In older adults, hospitalization is a major risk factor for deterioration of physical function, commonly identified through decline in mobility, muscle strength, gait performance, and independence in activities of daily living (ADL), typically assessed using tools such as gait speed, handgrip strength, and ADL scale [16, 17]. Functional recovery at discharge, defined as partial or total return to pre-hospital independence levels, as assessed by ADL, is generally low in this population [18] and highly variable depending on pre-hospital functional status and incident exposures, including disease severity, delirium, malnutrition, and immobilization [19]. Preexisting sarcopenia can be exacerbated during hospital stays driven by immobilization, inflammation, and malnutrition [20], further magnifying decline in muscle strength, mobility, and independence in ADL [21, 22]. Since sarcopenia has traditionally been well documented and more readily suspected in older adults with low BMI [20], it may be under-recognized and therefore overlooked in patients with obesity. This missed diagnosis has important consequences, considering that rehabilitation after acute care is often required in sarcopenic patients [23] and that sarcopenic obese older adults exhibit impaired recovery [24]. Indeed, the coexistence of excess adiposity and reduced muscle mass may contribute to poorer recovery through several interrelated mechanisms, including chronic low-grade inflammation, insulin resistance, anabolic resistance, reduced physical capacity, and the development or worsening of sarcopenia during hospitalization [1, 25]. These pathophysiological processes may further impair muscle function, mobility, responsiveness to rehabilitation, and other clinical outcomes, underscoring the importance of promptly recognizing and diagnosing sarcopenic obesity in acutely hospitalized older adults.
Recently, a standardized approach for the diagnosis of SO has been proposed by the European Society for Clinical Nutrition and Metabolism [26]. By applying it, the reported prevalence of SO in older hospitalized adults ranges between 4% in those with acute stroke [27] and 40% in those with severe obesity [28], suggesting that the characteristics of the selected population may account for the substantial variability observed in the prevalence of the condition. Focusing on geriatric rehabilitation, a prevalence of 4.5–5.3%, has been described; however, the association with functional outcomes at discharge has not been univocally reported [29, 30]. Indeed, the prevalence of SO in the geriatric acute care setting and its association with functional outcomes is currently unknown, yet this information is important to identify at-risk patients and guide personalized interventions to improve recovery trajectories. Therefore, this study was conducted to investigate the prevalence of SO diagnosed using the ESPEN-EASO approach in an acute care geriatric setting and to assess its associations with functional impairment.
Materials and methods
Study design and participants
In the timeframe from January 2023 to May 2025, 1639 older adults (≥65 years) were consecutively admitted to our acute Geriatric Unit within the context of a university hospital and were potentially eligible to be included in the study's retrospective and prospective cohorts, according to admission date before or from June 1, 2024, respectively. In both cohorts the same protocol was applied, and no additional resources were provided to favor data collection, which was left to routine practice. Exclusion criteria included younger age, lack of informed consent, and absence of key data such as reliable bioimpedance analysis (BIA) or handgrip strength (HGS) measurements as detailed in the following paragraphs, as well as incomplete information on functional status or because the patient was deceased in hospital (Fig. 1). All patients provided informed consent. The study was conducted in compliance with the Declaration of Helsinki, and the protocol was approved by the Regional Ethics Committee of Friuli Venezia Giulia (study number: 341_H2024H, approval number: 2024-Os-94).
Flowchart of study participants.
Comprehensive geriatric assessment and laboratory parameters
Data regarding patients’ demographic and living conditions were recorded at admission in the study ward. Clinical and laboratory data were obtained from the hospital electronic archive and from patients’ medical records. Laboratory parameters recorded in the study (plasma glucose, albumin, C-reactive protein, and creatinine, all by routinary hospital laboratory methodologies) were obtained at admission. All participants underwent, within 72 h of admission to the ward, a standardized comprehensive geriatric assessment for multidimensional evaluation, including functional, nutritional, and cognitive status, living condition, and medications used at home. The multidimensional assessment, including all testing for the aforementioned domains, was performed by the staff geriatrician responsible for the patient’s care, assigned at admission by predetermined rotational shifts. Functional status was assessed by Activities of Daily Living [31] to define the level of functional ability in basic care personal activities and by Instrumental Activities of Daily Living (IADL) to measure the level of independency in daily living [32]. Assessment of ADL was repeated during hospitalization and at discharge. Cognitive status was analyzed using the Short Portable Mental Status Questionnaire (SPMSQ) [33], while nutritional status was determined using the Mini Nutritional Assessment (MNA) [34]. Comorbidities number and severity were rated by the Cumulative Illness Rating Scale (CIRS) [35], and frailty by the Clinical Frailty Scale [36]. Impaired ADL was defined as ADL < 6 and impaired IADL as IADL < 8.
Body composition and anthropometry measures
Body height was measured using a 2-m inextensible tape; measurements were rounded to the nearest 0.1-cm. Body weight was measured to the nearest 0.1 kg on a scale chair or a lifter equipped with a weighing device, depending on patient conditions. Special attention was paid to using always the same device for each patient at admission and at the follow-up measurements. Body mass index (BMI, kg/m2) was calculated by dividing the actual weight (kg) by squared height (m). Body composition was assessed by BIA (BIA 101 Biva Pro, Akern, Pisa, Italy) following a previously published protocol [37]. Particular care was taken to ensure that patients were as far as possible from acute clinical interventions and conditions known to significantly alter hydration status. In particular, measurements were scheduled to avoid periods of intravenous fluid administration and other acute care procedures that could acutely modify fluid balance. Data points differing more than two standard deviations from the average were considered unreliable. A cutoff ≥27 kg/m2 was chosen for obesity screening in older adults, as it better correlates with excess fat in older adults [9]. Body fat mass (FM) and skeletal muscle mass (SMM) were recorded from BIA and expressed as percentage of body weight.
Handgrip strength
HGS measurements were performed by trained assessors using a calibrated hydraulic hand dynamometer (Jamar Hand dynamometer, JLW Instruments, Chicago, IL) following a standardized procedure to minimize inter-operator variability. After showing the procedure and recording the patient’s hand dominance, the participants performed two maximum-effort grips with each hand, starting with the right hand and then repeating the measurement with the left hand while sitting in a chair with a back support and fixed arm rests. Intervals of 30 s between each grip were observed. The average score was calculated and included in the analysis. Although formal test–retest reliability was not assessed within this study, the use of a well-established protocol and calibrated equipment was intended to ensure measurement consistency in agreement with available literature [2, 7, 9, 17, 38]. Data points differing more than two standard deviations in patients with physical, neurological, and cognitive impairments were considered unreliable.
SO evaluation
The evaluation of suspected SO followed the ESPEN-EASO approach [26]. The screening criteria included age-specific elevated BMI (≥ 27 kg m2) [9] in association with the presence of at least one clinical indicator of increased risk of sarcopenia among age, chronic comorbidities, and acute conditions [26]. Among patients who screened positive, SO was diagnosed in the presence of low HGS and of altered body composition defined as both low skeletal muscle mass and increased fat mass. The sex cut-offs for low HGS were <27 kg for males and <16 kg for females; those for low skeletal muscle mass (calculated as percentage of body weight) were <37% for males and <27.6% for females; and those for high fat mass (as percentage of body weight) were >27.3% for males and >40.7% for females [26, 39]. Depending on these criteria, participants were classified in four groups. Sarcopenic obese (SO) were defined on the basis of screening positive, low HGS, and both low skeletal muscle mass and increased fat mass. Obese (OB), despite positive screening, did not meet all the remaining criteria for SO at the diagnostic step. Patients with negative screening were defined as sarcopenic (SARC) in the presence of both low HGS and low SMM %BW and non-sarcopenic-non-obese (NS-NO), when not meeting both the criteria for SARC.
Outcomes and functional trajectories
The outcome of interest was functional status, defined as IADL and ADL collected at admission reflecting basal status, ADL during hospitalization, and at discharge. Functional recovery, measured as the difference of ADL at discharge and during hospitalization, was also included. ADL trajectories were identified by grouping all patients according to agglomerative hierarchical clustering, an unsupervised machine learning algorithm using Ward’s Method (SPSS version 26.0; IBM Corp., Armonk, NY, USA), based on the available three time points. According to distances in the dendrogram and sample numerosity, a 4-model was then chosen for further analyses. In addition, an ADL trajectory modeling grouping was performed based on a clinical approach according to (1) unmodified versus lower ADL in hospital compared to basal and (2) on recovered vs. non-recovered functional status at discharge. Trajectory analyses also allowed for the assessment of the relevance of basal functional status on outcomes without impact on multiple regression statistical power by variable number increase, as well as for better control for collinearity between ADL domains and other variables.
Statistical analysis
A priori power analysis was used to calculate the number of needed participants (G*Power 3.1.9, Heinrich Heine University, Duesseldorf, Germany). Based on clinical records from the same unit, we assumed an average ADL score for functional status of 4.5, 3.1, and 3.5 at admission, during hospital stay, and at discharge, respectively, suggesting the potential improvement between in-hospital and discharge to be about 0.4 ± 1.0. SO prevalence was assumed to be 10% [9, 21, 22]. Setting alpha = 0.05, a cohort of a total of 410 patients was then hypotized as required to observe the above-described effect in ADL in 41 SO patients, with adequate power (pi = 0.80). The number of participants was then increased by 10% in order to allow for compensation of potential effect size overestimation or SO prevalence underestimation in the specific study group. Regarding non-included patients for missing data, the missing not at random hypothesis was explored by comparison with observed values from the study cohort of 5 complete independent datasets of plausible estimates for missing data obtained by multiple imputation using the fully conditional specification (FCS) method, automatically identified as the best option by the statistical software. Data distribution for continuous variables was checked by the Shapiro-Wilk test. Differences in continuous variables among groups were assessed by two-tailed Student’s t-test for two-group and ANOVA for multiple-group comparison, respectively. For non-normally distributed or ordinal data, Mann–Whitney and Kruskal-Wallis tests were used as appropriate. For categorical variables, the chi-square test was used. When the null hypothesis was rejected, appropriate multiple-group, post hoc tests among group pairs were performed with correction for multiple comparisons according to Bonferroni. Incidence for clinical groups and clusters in trajectory modeling analyses was assessed by chi-square test of observed vs. expected data considering the hypothesis to the respective reference group, followed by Bonferroni correction. Relative risk for functional impairment in SARC, OB, and SO groups was assessed by chi-square tests and compared to the reference group NS-NO by z-tests on odds ratios on adjusted data. The association of age, cognitive and nutritional status with functional impairment was assessed by logistic regression, with stepwise and non-stepwise adjustment models. Models were designed by including variables with the aim to explore potential independence from each of the following domains: demographics, clinical status, and functional status prior to subacute events leading to hospitalization. In all tests, P-values < 0.05 were considered significant. The statistical analysis was conducted using the SPSS for Windows software package (version 26.0; IBM Corp., Armonk, NY, USA). R Foundation for Statistical Computing Software (version 4.41) was specifically used for relative risk comparison analyses.
Results
Baseline characteristics and prevalence of sarcopenic obesity and of other body phenotypes using the ESPEN-EASO approach
Of a total of 1639 patients admitted to the Unit in the timeframe from January 2023 to May 2025, 453 patients were included in the study, while 1186 did not meet inclusion criteria, mainly because of lack of data, and were excluded from the study. While some uncertainty due to missing data and potential selection bias cannot be fully ruled out, analysis of main demographics, number of medications, laboratory parameters, and length of stay showed no difference between included and non-included patients (Supplementary Table 1). Furthermore, no significant difference was observed when comparing data from the study cohort with five different complete sets of plausible estimates for missing data for non-included patients (Supplementary Table 2). The demographic and clinical characteristics of the included patients are detailed in Table 1. No difference was observed between retrospective and prospective groups in any parameter (Supplementary Table 3). In the whole study cohort at the ESPEN-EASO algorithm screening step, all patients had acute conditions on top of a high burden of comorbidities, therefore meeting clinical criteria for inclusion. Besides, all but 15 patients also met the age (>70 y old) criterion. One hundred one (22.3%) patients were also positive for obesity screening and, therefore, following the ESPEN-EASO approach, were included in the SO diagnosis assessment step. Seventy-nine (78.2%) demonstrated low handgrip strength, 65 (64.4%) reduced skeletal muscle mass, and 54 (53.5%) increased fat mass. Thirty-six (7.9%, 14 females and 22 males) obese patients showed concomitantly reduced skeletal muscle mass and HGS and increased fat mass; therefore, they fully met ESPEN-EASO diagnostic criteria for SO. To test the clinical relevance of the screening phase in the current setting, we also applied diagnostic criteria independently of screening and found that prevalence increased to 13.9% with a trend towards a higher rate of prevalence in males compared with females (Fig. 2). However, at variance with the full application of the ESPEN-EASO approach, omitting the screening step led to the identification of a putative SO cohort with a lower average BMI (27.67 ± 5.18 vs. 31.61 ± 4.08 kg/m2, P < 0.0001), which paradoxically included 48.6% of patients with BMI < 27 kg/m2, 35.7% with BMI < 25 kg/m2 and a minimum value of 20.71 kg/m2 for the same parameter. The remaining 65 (14.3%) older adults with a BMI ≥ 27 kg/m2 did not fully meet all the criteria for diagnosis of SO and were therefore classified as affected by obesity (OB). Patients with a negative screening for obesity (n = 352, 77.7%) were assessed for the presence of sarcopenia. Ninety-eight older adults showed concomitant low HGS and low SMM % and were therefore classified as sarcopenic (SARC). The remaining 254 patients with either low HGS (n = 216) or low SMM % (n = 15) and/or increased FM% (n = 17) or none of the aforementioned criteria (n = 21) were classified as non-sarcopenic non-obese (NS-NO). This latter group was considered the reference category in the relative risk assessment analysis.
Positive screening for obesity is defined as BMI ≥ 27 kg/m2. Low HGS is defined as <27 kg in males and <16 kg in females. For SO diagnosis, low skeletal muscle mass is defined as a percentage SMM < 37% in males and < 27.6% in females. Increased fat mass is defined as percentage fat mass >27.3% in males and >40.7% in females. SO: sarcopenic obesity; NS-NO: non-sarcopenic, non-obese.
Body phenotypes, sarcopenic obesity, clinical and laboratory parameters
Mean comparison analyses showed that patients in the SARC groups were slightly older (+3.67 y) than those in the OB groups, while females were more prevalent (+19.7%) in the OB group. According to the Mini Nutritional Assessment, patients in the OB and in the SO groups showed a better nutritional score than those in the NS-NO and SARC groups (+2.08 to −2.45 MNA points). A similar trend was demonstrated for cognitive function assessed by SPSMQ, although it did not reach statistical significance. No significant differences among groups in the tested laboratory parameters (glucose, albumin, C-reactive protein, bis-1 GFR, and hemoglobin) were detected, as well as in length of hospital stay (Table 1).
Body phenotypes, sarcopenic obesity, and functional status
Patients with obesity alone demonstrated better IADL scores compared with those in the NS-NO, SARC, and SO groups (+1.06, +1.24, and +1.25, respectively, P < 0.05) whereas no significant differences in ADL scores were observed among groups at baseline, in hospital, or at discharge (Table 1). No significant differences among groups were observed in the change in ADL score between admission and hospitalization. In contrast, when considering the change in ADL score between hospitalization and discharge, patients with obesity alone demonstrated greater functional recovery compared with the other three groups, whereas the SARC group showed the poorest recovery (Table 1). Table 2 shows the prevalence of patients with impaired ADL (defined as ADL < 6) and IADL (defined as IADL < 8) in the different study groups. Considering IADL, the number of patients with IADL < 8 was lowest (P < 0.02) in OB compared with the other groups, while the number of patients with impaired ADL at admission, during hospitalization, and at discharge was not statistically different among groups. With regard to ADL change directions, about half of the patients showed a functional loss during hospital stay compared to basal, with no difference among groups, while OB demonstrated a recovery of ADL at discharge in a significant number of patients compared to other groups (+13.3%; P < 0.05). Finally, compared with older adults with intact functional status defined as an IADL score of 8 and an ADL score of 6, those with impaired ADL and IADL were older with worse nutritional status and deteriorated cognitive function (Table 3).
In order to further investigate the impact of SO on functional status changes, also considering the potential role of basal levels, ADL trajectory analysis was performed, allowing for the identification of the principal models characterized by specific patterns of functional changes over time. In particular, 4-model hierarchical cluster analysis computationally identified four different clusters summarizing main trajectories in the study group: patients classifiable as independent (average ADL > 4) maintaining the status throughout the study, patients with moderate to severe loss of function defined as followed by recovery, patients with loss of function not followed by recovery at discharge, and patients constantly presenting very low average ADL ( < 2) at all time points (Fig. 3A). Among patients losing functional autonomy, those who did not improve at discharge did not differ for age, BMI, laboratory values, comorbidities (CIRS), or nutritional status (MNA) but presented higher cognitive impairment (SPMSQ) and frailty compared to those who recovered (Supplementary Table 4). Interestingly, SO was more frequent in patients from clusters characterized by functional decline from basal levels, with significantly higher values in those who did not recover (Fig. 3B, C). We also analyzed trajectory models based on a clinical approach, and, consistent with previously described results, this analysis showed that SO incidence was specifically higher in patients losing basal autonomy with no improvement at discharge. Besides, obesity was more frequent in those who showed functional recovery, defined as the change of ADL between in-hospital and discharge time points (Fig. 3D).
A Patterns have been identified by 4-model hierarchical cluster analyses of changes over time considering basal, in-hospital, and discharge assessments. Cluster 1: patients with moderate to severe loss of function followed by recovery; Cluster 2: patients classifiable as independent (average ADL > 4) maintaining the status throughout the study; Cluster 3: patients constantly presenting very low average ADL ( < 2) at all timepoints and Cluster 4: patients with loss of function not followed by recovery at discharge. Data are represented by average ± standard deviation. B Relative frequency of study groups in trajectory models. Data are normalized for the reference group incidence (NS-NO) in order to better allow for pattern comparison. *P < 0.05 vs. same group in other clusters; #P < 0.05 vs. same group in clusters 1 and 4. C Relative trajectory model attribution frequency within SARC, OB, and SO study groups, normalized by attributions of each cluster to the reference (NS-NO) for better pattern evaluation. Within each group, data not sharing the same letter differ (P< 0.05 after Bonferroni correction) in relative cluster attribution. D Relative frequency of study groups in a clinical 3-model trajectory analysis based on ADL changes in hospital and at recovery. Data are normalized for the reference group incidence (NS-NO) in order to better allow for pattern comparison. *P < 0.05 vs. same group in other clusters. NS-NO: non-sarcopenic, non-obese; SARC: sarcopenic, OB: obese, SO: sarcopenic obesity. All comparisons between groups by chi-square with Bonferroni correction for multiple comparisons.
Multivariate associations of body phenotypes with functional and clinical variables
When the NS-NO phenotype was taken as reference, in the unadjusted model only SO was associated with an increased risk of impaired ADL at discharge, while OB demonstrated an increased probability of functional recovery at dismissal from the hospital. (Table 4). In adjusted models considering severity of disease (CRP to albumin ratio) and comorbidities (CIRS severity), the association of SO with functional decline at discharge was confirmed while that of OB with improved recovery was not. Results were also independent of age, sex, and basal ADL. Moreover, with regard to increased risk of functional impairment at discharge in SO individuals, sensitivity analysis, performed by repeating risk assessment and also excluding patients under the 15th, 20th, and 25th percentiles for basal ADL (basal ADL < 2 to < 4) in a stepwise approach, confirmed robustness of observed results (Supplementary Table 5). In contrast, none of the body phenotypes was independently associated with an increased risk of impaired IADL. After correction for study group and confounding factors in multivariate analysis, older age, malnutrition, and poor cognitive function were associated with impaired ADL at admission and at discharge and with impaired IADL independently of body phenotype. No associations were observed with functional recovery (Table 5).
Discussion
In this hospital-based cohort study, using the ESPEN-EASO approach for the diagnosis of sarcopenic obesity, the prevalence of the condition was 7.9%. Although there was no difference in ADL at admission among groups, obesity alone was associated with the best recovery of ADL at discharge compared with the other phenotypes. In contrast to patients affected by only obesity or sarcopenia, older adults with SO showed a specific association with loss of basal function and higher risk of impaired ADL at discharge, suggesting that SO but not obesity accelerates functional decline during hospital stay.
Previous studies have reported substantial heterogeneity both in the estimated prevalence of sarcopenic obesity among older adults and in its associated clinical outcomes and complications, with some studies showing significant associations while others reported weaker or non-significant correlations [40]. In addition, very few studies have addressed the issue of the prevalence of sarcopenic obesity among older adults in the hospital setting and of its consequences on functional status. For instance, Yoshimura et al., applying the ESPEN-EASO approach in a cohort of older patients with stroke undergoing rehabilitation, reported a prevalence of sarcopenic obesity of 4.5%; those with SO were less likely to show improvements in ADL at discharge [30]. The same authors, by using the EWGSOP2 criteria to diagnose sarcopenia and several parameters (BMI, percentage body fat) to define obesity found in post-acute rehabilitation, a prevalence of SO varying from 2.1% to 40.7%, with % FM negatively associated with functional improvement and home discharge in post-acute rehabilitation [41]. Similarly, by using the ESPEN-EASO approach, Shimizu et al. described a relatively low prevalence of SO, ranging from 4.4% to 5.3%, by applying different cut-offs for low skeletal muscle mass and increased body fat in older adults undergoing rehabilitation [29]. In this latter study SO was not associated with impaired functional outcomes. Finally, by using percentage body fat mass to define obesity and the EWGSOP2 criteria to diagnose sarcopenia, Atmis et al. [11] observed a relatively high prevalence of the condition (21%) in hospitalized older patients, which increased to 40% [28] in another study applying the ESPEN-EASO approach to a cohort of hospitalized older adults with severe obesity. In both studies the relationship with functional outcomes was not reported. Our study expands these previous findings by examining a hospital-based very old population, by applying the ESPEN-EASO approach, and by considering several domains included in the comprehensive geriatric assessment. In this study we used a BMI cut-off of ≥27 kg/m2 to screen for obesity. Our choice is based on previous studies conducted specifically in older adults showing that the ≥30 kg/m2 threshold shows a low sensitivity for the diagnosis of obesity and that a cut-off ≥27 kg/m2 better correlates with excess fat percentage [9, 42]. When screening was not applied and the diagnosis of SO was only based on low HGS and altered body composition, the putative prevalence of the condition rose to 13.9%. Although this figure may be in line with previous reports [29], in our cohort this approach led to paradoxically classifying as SO a relevant number of patients, which, according to BMI, would not meet any conventional clinical criterion for obesity or even overweight. Taken together, these findings underscore the urgent need for dedicated screening criteria for obesity tailored to older adults, a growing population with a high burden of chronic conditions, multimorbidity, and use of healthcare services.
The association between sarcopenia, ADLs, and dependency in older adults has been investigated by a few studies, with different results. A longitudinal study conducted in middle-aged and older adults showed that individuals with sarcopenia have a higher risk of ADL disability and more rapid decline in functional independence over time compared with non-sarcopenic individuals [43]. Also, a systematic review and meta-analysis confirmed that impaired muscle mass, strength, and physical performance—core components of sarcopenia—are strongly associated with poorer ADL outcomes in older populations, supporting a consistent dose–response relationship between muscle impairment and functional limitation [44]. In contrast, a recent consensus report found limited and heterogeneous evidence linking sarcopenia to mobility impairment and ADL disability, and therefore the associations were rated as inconclusive [45]. In this study we did not detect either a higher prevalence of impaired ADL at any explored time point in non-obese sarcopenic patients compared with other groups or an increased risk of compromised ADL. One possible explanation for this finding is that most of the patients (85%) in the control group were presarcopenic, potentially reducing the functional differences between the study groups. Nonetheless, unlike the other phenotypes, SO demonstrated a clear increase in the risk of impaired ADL at discharge. This finding was also independent of confounding factors, including age, sex, and clinical status, as well as basal ADL, a known major determinant for functional outcome. These results obtained for the first time in hospitalized older adults acutely ill by using the ESPEN-EASO approach expand previous findings obtained in other settings [29, 30, 46]. The current findings also demonstrate that unlike sarcopenic obese patients affected by only obesity, they do not share the same probability of increased functional decline at discharge, suggesting a protecting role of obesity against loss of functional independence during hospitalization for acute conditions [47]. Indeed, evidence comparing functional outcomes across body composition phenotypes suggests meaningful differences in ADL between obesity, sarcopenia, and sarcopenic obesity. In particular, isolated obesity does not appear to be consistently associated with ADL disability in older adults compared with non-obese individuals [48]. In contrast, sarcopenic obesity has been more consistently associated with impaired functional status, including greater risk of ADL and IADL limitations, suggesting a synergistic detrimental effect of excess adiposity combined with low muscle mass and function. To this regard, Baumgartner et al. demonstrated that sarcopenic obesity significantly increased the risk of incident disability compared with obesity or sarcopenia alone, highlighting the clinical relevance of this phenotype [49]. Similarly, studies in clinical populations, including stroke rehabilitation patients, have shown that sarcopenic obesity is associated with lower functional independence scores, whereas obesity alone is not a consistent predictor of poorer ADL outcomes [24]. Population-based data further provide evidence that sarcopenic obesity is more strongly related to functional limitation than isolated obesity, although results may vary depending on definitions and adjustment for confounders [38]. Overall, these findings support the concept that reduced muscle mass and quality, rather than excess body weight per se, are the primary drivers of functional impairment and help contextualize our observation that obesity alone may be associated with relatively preserved or improved ADL recovery in the short term.
In addition to sarcopenic obesity, older age, poor nutritional status, and deteriorated cognitive function were independently associated with impaired functional status. These results are in line with those previously reported by Bahat et al. [50] and by Welch et al. [51], suggesting that malnutrition and cognitive impairment play a prominent role in impaired physical function in hospitalized older adults. Malnutrition may contribute to impaired physical function through decreased muscle protein synthesis, chronic low-grade inflammation, and accelerated loss of skeletal muscle mass and strength, all of which are key mechanisms underlying sarcopenia and frailty in older adults [52, 53]. Furthermore, malnourished older individuals frequently exhibit reduced handgrip strength and lower walking speed, suggesting that inadequate nutritional status is closely associated with poor physical performance [54].
Strengths and limitations
This study has several strengths, including the hospital-based setting, the availability of a complete comprehensive geriatric assessment, and the diagnosis of sarcopenic obesity based on the most recent available approach. However, potential limitations should be considered when interpreting the results. First, because of a low prevalence of older adults with normal HGS and SMM (n = 21, 4%), stratification of presarcopenic from not presarcopenic patients was not possible. Second, the cross-sectional study design limits causal relationships' interpretation, and the findings should be regarded as associations rather than causal effects. Additionally, body composition and handgrip strength were only assessed at hospital admission, with no follow-up measurements available. This prevents any evaluation of potential changes of these parameters during hospital stay and at discharge as well as their associations with variations of functional status over time. Sample number, with particular regard to identified SO patients, while being in line with other studies and supported by power analysis for the investigated outcomes, does not allow for further and more in-depth analyses, including complex covariate model testing. Larger datasets may allow for a reduced degree of uncertainty in estimates assessment as well as more in-depth analyses. Finally, the mono-centric nature of the study may restrict the external validity and reduce the generalizability of the results to broader and diverse populations.
Conclusions
Sarcopenic obesity accounts for approximately 8% of body phenotypes in older adults hospitalized for acute conditions. Obesity and SO are characterized by different functional outcomes, with SO tending to show a higher risk of functional impairment with lower recovery at discharge and OB a greater likelihood of functional recovery. These results demonstrate the heterogeneity of obese older patients in the acute geriatric setting and suggest that screening and assessment for SO should be implemented in hospital geriatric care in order to early identify those at highest risk of functional decline and increased dependency in ADL [55].
Data availability
Data not shared for ethics and privacy reasons.
References
Prado CM, Batsis JA, Donini LM, Gonzalez MC, Siervo M. Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol. 2024;20:261–77. https://doi.org/10.1038/s41574-023-00943-z.
Li R, Chen X, Tang H, Luo S, Lian R, Zhang W, et al. Sarcopenic obesity and falls in older adults: A validation study of ESPEN/EASO criteria and modifications in Western China communities. Arch Gerontol Geriatr. 2024;127:105557 https://doi.org/10.1016/j.archger.2024.105557.
Meng P, Hu YX, Fan L, Zhang Y, Zhang MX, Sun J, et al. Sarcopenia and sarcopenic obesity among men aged 80 years and older in Beijing: prevalence and its association with functional performance. Geriatr Gerontol Int. 2014;14:29–35. https://doi.org/10.1111/ggi.12211.
Kong HH, Won CW, Kim W. Effect of sarcopenic obesity on deterioration of physical function in the elderly. Arch Gerontol Geriatr. 2020;89:104065 https://doi.org/10.1016/j.archger.2020.104065.
Tanaka M, Ikezoe T, Ichihashi N, Tabara Y, Nakayama T, Takahashi Y, et al. Relationship of low muscle mass and obesity with physical function in community dwelling older adults: Results from the Nagahama study. Arch Gerontol Geriatr. 2020;88:103987 https://doi.org/10.1016/j.archger.2019.103987.
Someya Y, Tamura Y, Kaga H, Sugimoto D, Kadowaki S, Suzuki R, et al. Sarcopenic obesity is associated with cognitive impairment in community-dwelling older adults: The Bunkyo Health Study. Clin Nut. 2022;41:1046–51. https://doi.org/10.1016/j.clnu.2022.03.017.
Gortan Cappellari G, Semolic A, Zanetti M, Vinci P, Ius M, Guarnieri G, et al. Sarcopenic obesity in free-living older adults detected by the ESPEN-EASO consensus diagnostic algorithm: validation in an Italian cohort and predictive value of insulin resistance and altered plasma ghrelin profile. Metabolism. 2023;145:155595 https://doi.org/10.1016/j.metabol.2023.155595.
Öztürk, Türkbeyler ZA, İH, Abiyev A, Kul S, Edizer B, et al. Health-related quality of life and fall risk associated with age-related body composition changes; sarcopenia, obesity and sarcopenic obesity. Intern Med J. 2018;48:973–81. https://doi.org/10.1111/imj.13935.
Benz E, Pinel A, Guillet C, Capel F, Pereira B, De Antonio M, et al. Sarcopenia and Sarcopenic Obesity and Mortality Among Older People. JAMA Netw Open. 2024;7:e243604 https://doi.org/10.1001/jamanetworkopen.2024.3604.
Silay K, Selvi Oztorun H. Sarcopenic obesity is linked to worse clinical outcomes than sarcopenia or obesity alone in hospitalized older adults. BMC Geriatr. 2025;25:443 https://doi.org/10.1186/s12877-025-06105-2.
Atmis V, Yalcin A, Silay K, Ulutas S, Bahsi R, Turgut T, et al. The relationship between all-cause mortality sarcopenia and sarcopenic obesity among hospitalized older people. Aging Clin Exp Res. 2019;31:1563–72. https://doi.org/10.1007/s40520-019-01277-5.
Donini LM, Busetto L, Bauer JM, Bischoff S, Boirie Y, Cederholm T, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr. 2020;39:2368–88. https://doi.org/10.1016/j.clnu.2019.11.024.
Gao Q, Mei F, Shang Y, Hu K, Chen F, Zhao L, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr. 2021;40:4633–41. https://doi.org/10.1016/j.clnu.2021.06.009.
Liu C, Wong PY, Chung YL, Chow SK, Cheung WH, Law SW, et al. Deciphering the “obesity paradox” in the elderly: a systematic review and meta-analysis of sarcopenic obesity. Obes Rev. 2023;24:e13534 https://doi.org/10.1111/obr.13534.
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31. https://doi.org/10.1093/ageing/afy169.
de Carvalho ACM, Gomes CS, Menezes KVRS, Fernandes J, Azevedo IG, Corrêa LCAC, et al. Hospitalization is associated with handgrip strength decline in older adults: a longitudinal study. Aging Clin Exp Res. 2022;34:619–24. https://doi.org/10.1007/s40520-021-01954-4.
Duan-Porter W, Vo TN, Ullman K, Langsetmo L, Strotmeyer ES, Taylor BC, et al. Hospitalization-associated change in gait speed and risk of functional limitations for older adults. J Gerontol A Biol Sci Med Sci. 2019;74:1657–63. https://doi.org/10.1093/gerona/glz027.
Boyd CM, Landefeld CS, Counsell SR, Palmer RM, Fortinsky RH, Kresevic D, et al. Recovery of activities of daily living in older adults after hospitalization for acute medical illness. J Am Geriatr Soc. 2008;56:2171–9. https://doi.org/10.1111/j.1532-5415.2008.02023.x.
Geyskens L, Jeuris A, Deschodt M, Van Grootven B, Gielen E, Flamaing J. Patient-related risk factors for in-hospital functional decline in older adults: a systematic review and meta-analysis. Age Ageing. 2022;51:afac007. https://doi.org/10.1093/ageing/afac007.
Martone AM, Bianchi L, Abete P, Bellelli G, Bo M, Cherubini A, et al. The incidence of sarcopenia among hospitalized older patients: results from the Glisten study. J Cachexia Sarcopenia Muscle. 2017;8:907–14. https://doi.org/10.1002/jcsm.12224.
Welch, K C, Hassan-Smith, A Z, Greig, M C, et al. Acute sarcopenia secondary to hospitalisation—an emerging condition affecting older adults. Aging Dis. 2018;9:151–64. https://doi.org/10.14336/AD.2017.0315.
Morandi A, Onder G, Fodri L, Sanniti A, Schnelle J, Simmons S, et al. The association between the probability of sarcopenia and functional outcomes in older patients undergoing in-hospital rehabilitation. J Am Med Dir Assoc. 2015;16:951–6. https://doi.org/10.1016/j.jamda.2015.05.010.
Yagi T, Inoue T, Ogawa M, Shimada Y, Heguri Y, Okada R, et al. Sarcopenia affects activities of daily living recovery and hospitalization costs in older adults in convalescent rehabilitation wards. Eur Geriatr Med. 2021;12:1237–45. https://doi.org/10.1007/s41999-021-00552-x.
Matsushita T, Nishioka S, Taguchi S, Yamanouchi A, Nakashima R, Wakabayashi H. Sarcopenic obesity and activities of daily living in stroke rehabilitation patients: a cross-sectional study. Healthcare (Basel). 2020;8:255 https://doi.org/10.3390/healthcare8030255.
Koliaki C, Liatis S, Dalamaga M, Kokkinos A. Sarcopenic obesity: epidemiologic evidence, pathophysiology, and therapeutic perspectives. Curr Obes Rep. 2019;8:458–71. https://doi.org/10.1007/s13679-019-00359-9.
Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr. 2022;41:990–1000. https://doi.org/10.1016/j.clnu.2021.11.014.
Abe T, Yoshimura Y, Sato Y, Nagano F, Matsumoto A. Applicability of the diagnostic criteria for sarcopenic obesity defined by ESPEN/EASO criteria in acutely admitted patients with stroke: prevalence and association with outcomes. J Nutr Sci Vitaminol. 2023;69:454–62. https://doi.org/10.3177/jnsv.69.454.
Danielewicz AL, Marra A, Tringali G, Micheli R, Abbruzzese L, Fanari P, et al. Analysis of sarcopenic obesity prevalence and diagnostic agreement according to the 2022 ESPEN and EASO consensus in hospitalized older adults with severe obesity. Front Endocrinol (Lausanne). 2024;15:1366229. https://doi.org/10.3389/fendo.2024.1366229.
Shimizu A, Maeda K, Ueshima J, Inoue T, Murotani K, Ohno T, et al. Prevalence of sarcopenic obesity based on newly proposed diagnostic criteria and functional outcomes in older adults undergoing rehabilitation. Mech Ageing Dev. 2022;208:111728 https://doi.org/10.1016/j.mad.2022.111728.
Yoshimura Y, Wakabayashi H, Nagano F, Matsumoto A, Shimazu S, Shiraishi A, et al. The Applicability of the ESPEN and EASO-Defined diagnostic criteria for sarcopenic obesity in japanese patients after stroke: prevalence and association with outcomes. Nutrients. 2022;14:4205 https://doi.org/10.3390/nu14194205.
Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist. 1970;10:20–30. https://doi.org/10.1093/geront/10.1_part_1.20.
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.
Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc. 1975;23:433–41. https://doi.org/10.1111/j.1532-5415.1975.
Guigoz Y. The Mini Nutritional Assessment (MNA) review of the literature—what does it tell us? J Nutr Health Aging. 2006;10:466–85.
Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622–6. https://doi.org/10.1111/j.1532-5415.1968.tb02103.x.
Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95. https://doi.org/10.1503/cmaj.050051.
Sanson G, Doriguzzi L, Garbari P, Ruggiero MJ, Valentinuzzo I, Mettulio T, et al. The severity of early fluid overload assessed by bioelectrical vector impedance as an independent risk factor for longer patient care after cardiac surgery. Clin Nutr. 2024;43:803–14. https://doi.org/10.1016/j.clnu.2024.02.007.
Murawiak M, Lewandowicz-Czarnecka M, Kaczmarek B, Deskur-Śmielecka E, Wieczorowska-Tobis K, Krzymińska-Siemaszko R. Sarcopenia, obesity, and sarcopenic obesity in relation to functional limitations in older adults. J Clin Med. 2026;15:1000 https://doi.org/10.3390/jcm15031000.
Bahat G, Kilic C, Topcu Y, Aydin K, Karan MA. Fat percentage cutoff values to define obesity and prevalence of sarcopenic obesity in community-dwelling older adults in Turkey. Aging Male. 2020;23:477–82. https://doi.org/10.1080/13685538.2018.1530208.
Veronese N, Ragusa FS, Pegreffi F, Dominguez LJ, Barbagallo M, Zanetti M, et al. Sarcopenic obesity and health outcomes: an umbrella review of systematic reviews with meta-analysis. J Cachexia Sarcopenia Muscle. 2024;15:1264–74. https://doi.org/10.1002/jcsm.13502.
Yoshimura Y, Wakabayashi H, Nagano F, Bise T, Shimazu S, Kudo M, et al. Sarcopenic obesity is associated with activities of daily living and home discharge in post-acute rehabilitation. J Am Med Dir Assoc. 2020;21:1475–80. https://doi.org/10.1016/j.jamda.2020.03.029.
Batsis JA, Mackenzie TA, Bartels SJ, Sahakyan KR, Somers VK, Lopez-Jimenez F. Diagnostic accuracy of body mass index to identify obesity in older adults: NHANES 1999-2004. Int J Obes (Lond). 2016;40:761–7. https://doi.org/10.1038/ijo.2015.243.
Lan L, Shao S, Zheng X. Associations between Sarcopenia and trajectories of activities of daily living disability: a nationwide longitudinal study of middle-aged and older adults in China from 2011 to 2018. Arch Public Health. 2024;82:97 https://doi.org/10.1186/s13690-024-01329-x.
Wang DXM, Yao J, Zirek Y, Reijnierse EM, Maier AB. Muscle mass, strength, and physical performance predicting activities of daily living: a meta-analysis. J Cachexia Sarcopenia Muscle. 2020;11:3–25. https://doi.org/10.1002/jcsm.12502.
Beaudart C, Alcazar J, Aprahamian I, Batsis JA, Yamada Y, Prado CM, et al. Health outcomes of sarcopenia: a consensus report by the outcome working group of the Global Leadership Initiative in Sarcopenia (GLIS). Aging Clin Exp Res. 2025;37:100 https://doi.org/10.1007/s40520-025-02995-9.
Scott D, Blyth F, Naganathan V, Le Couteur DG, Handelsman DJ, Waite LM, et al. Sarcopenia prevalence and functional outcomes in older men with obesity: comparing the use of the EWGSOP2 sarcopenia versus ESPEN-EASO sarcopenic obesity consensus definitions. Clin Nutr. 2023;42:1610–18. https://doi.org/10.1016/j.clnu.2023.07.014.
Sun W, Xian Y, Huang Y, Sun W, Liu R, Li F, et al. Obesity is associated with better survival and functional outcome after acute intracerebral hemorrhage. J Neurol Sci. 2016;370:140–4. https://doi.org/10.1016/j.jns.2016.09.029.
Lingying W, Hong Z, Hongxiu C, Ziyi H, Mei F, Menglin T, et al. Association of body mass index with disability in activities of daily living in older adults: a systematic review of the literature based on longitudinal data. BMC Public Health. 2025;25:6. https://doi.org/10.1186/s12889-024-21234-w.
Baumgartner RN, Wayne SJ, Waters DL, Janssen I, Gallagher D, Morley JE. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res. 2004;12:1995–2004. https://doi.org/10.1038/oby.2004.250.
Bahat G, Kilic C, Ozkok S, Ozturk S, Karan MA. Associations of sarcopenic obesity versus sarcopenia alone with functionality. Clin Nutr. 2021;40:2851–59. https://doi.org/10.1016/j.clnu.2021.04.002.
Welch C, Chen Y, Hartley P, Naughton C, Martinez-Velilla N, Stein D, et al. New horizons in hospital-associated deconditioning: a global condition of body and mind. Age Ageing. 2024;53:afae241 https://doi.org/10.1093/ageing/afae241.
Sieber CC. Malnutrition and sarcopenia. Aging Clin Exp Res. 2019;31:793–8. https://doi.org/10.1007/s40520-019-01170-1.
Cerri AP, Bellelli G, Mazzone A, Pittella F, Landi F, Zambon A, et al. Sarcopenia and malnutrition in acutely ill hospitalized elderly: prevalence and outcomes. Clin Nutr. 2015;34:745–51. https://doi.org/10.1016/j.clnu.2014.08.015.
Coelho-Júnior HJ, Álvarez-Bustos A, Russo A, Rodriguez-Mañas L, Landi F, Marzetti E. Associations between malnutrition and physical performance, sarcopenia, and frailty in older adults. BMC Geriatr. 2025;25:612 https://doi.org/10.1186/s12877-025-06274-0.
Barazzoni R, Cederholm T, Zanetti M, Gortan Cappellari G. Defining and diagnosing sarcopenia: Is the glass now half full? Metabolism. 2023;143:155558 https://doi.org/10.1016/j.metabol.2023.155558.
Acknowledgments
None.
Funding
Open access funding provided by Università degli Studi di Trieste within the CRUI-CARE Agreement.
Author information
Authors and Affiliations
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
Gianluca Gortan Cappellari, Rocco Barazzoni, Matteo Bianchini, Carlo Cortese, Anna Rizza, Giovanni Zampieri & Michela Zanetti
Dietetics School, University of Trieste, Pordenone Campus, Pordenone, Italy
Gianluca Gortan Cappellari, Sabrina Rampazzo & Michela Zanetti
Saint Camillus International University of Health Sciences, Faculty of Medicine, Rome, Italy
Nicola Veronese
UCO Geriatria, ASUGI, Trieste, Italy
Paolo De Colle, Giuseppe Castiglia, Matteo Bianchini, Carlo Cortese, Anna Rizza & Michela Zanetti
Piattaforma di Dietetica e Nutrizione, Azienda Sanitaria Friuli Occidentale, Pordenone, Italy
Sabrina Rampazzo
Authors
- Gianluca Gortan Cappellari
- Rocco Barazzoni
- Nicola Veronese
- Paolo De Colle
- Giuseppe Castiglia
- Matteo Bianchini
- Carlo Cortese
- Sabrina Rampazzo
- Anna Rizza
- Giovanni Zampieri
- Michela Zanetti
Contributions
R.B. and M.Z. conceived the study; M.B., C.C., A.R., and G.Z. collected the data; G.C., P.D.C., and S.R. reviewed the collected data; G.G.C. performed statistical analysis and contributed to the manuscript; M.Z. and R.B. drafted the manuscript; N.V. supervised manuscript writing and discussion; and all authors approved the final version of the manuscript.
Corresponding author
Correspondence to Michela Zanetti.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethical approval
The study was approved by the Regional Ethics Committee (CEUR) of the Friuli Venezia Giulia region (study number: 341_H2024H, approval number: 2024-Os-94).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gortan Cappellari, G., Barazzoni, R., Veronese, N. et al. Prevalence and impact of sarcopenic obesity at hospital admission according to ESPEN-EASO approach on functional status of older adults: results of a retrospective and prospective observational study. Eur J Clin Nutr (2026). https://doi.org/10.1038/s41430-026-01835-x
Received: 11 September 2025
Revised: 09 September 2026
Accepted: 24 September 2026
Published: 10 October 2026
Version of record: 10 October 2026
DOI: https://doi.org/10.1038/s41430-026-01835-x
来源:Nature 健康护理主题 · nature.com